Uncategorized
Oric to advance prostate cancer drug to Phase 3, but combo choice raises doubts
Oric to advance prostate cancer drug to Phase 3, but combo choice raises doubts
Oric Pharmaceuticals on Tuesday detailed its plans to advance a PRC2 inhibitor into a registrational program for prostate cancer after sharing results from a Phase 1b trial.
But the company’s shares {$ORIC} dropped by as … Read More